Muscular dystrophies and mitochondrial myopathies: Pathology review

Last updated: November 01, 2022

Muscular dystrophies and mitochondrial myopathies: Pathology review

Firdus

Firdus

Nasal cavity and larynx histology
Pediatric upper airway conditions: Clinical
Nasal, oral and pharyngeal diseases: Pathology review
Pediatric ear, nose, and throat conditions: Clinical
Tympanic membrane perforation
Warthin tumor
Dizziness and vertigo: Clinical
Vertigo: Pathology review
Neck trauma: Clinical
Eye conditions: Retinal disorders: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Premature rupture of membranes: Clinical
Pregnancy
Abdominal pain: Clinical
Virilization: Clinical
Sexually transmitted infections: Clinical
Contraception: Clinical
Vulvar cancer: Clinical
Urinary incontinence: Pathology review
Vulvovaginitis: Clinical
Vaginal cancer: Clinical
Infertility: Clinical
Cervical cancer: Clinical
Uterine stimulants and relaxants
Menstrual cycle
Endometritis
Preeclampsia & eclampsia
Gestational diabetes
Gestational hypertension
Placenta accreta
Preterm labor
Uterine disorders: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Vaginal and vulvar disorders: Pathology review
Complications during pregnancy: Pathology review
Pediatric gastrointestinal bleeding: Clinical
Pediatric infectious rashes: Clinical
Pediatric brain tumors
Pediatric brain tumors: Pathology review
Pediatric vomiting: Clinical
Congenital heart defects: Clinical
Congenital pulmonary airway malformation
Congenital gastrointestinal disorders: Pathology review
Congenital neurological disorders: Pathology review
Pediatric urological conditions: Clinical
Dandy-Walker malformation
Congenital adrenal hyperplasia: Clinical
Beta-thalassemia
Neonatal jaundice: Clinical
Anaphylaxis
Food allergies and EpiPens: Information for patients and families (The Primary School)
Pediatric allergies: Clinical
Food allergy
Vaccinations: Clinical
Allergic rhinitis
Pediatric lower airway conditions: Clinical
Pediatric upper airway conditions: Clinical
Pediatric bone tumors: Clinical
Pediatric ophthalmological conditions: Clinical
Constitutional growth delay
Growth and development
Growth hormone deficiency
Delayed puberty
Precocious and delayed puberty: Clinical
Hemophilia
Coagulation disorders: Pathology review
Bleeding disorders: Clinical
Osteomalacia and rickets
Achondroplasia
Asthma
Asthma: Clinical
Asthma: Information for patients and families (The Primary School)
Sleep apnea
Nasal polyps
Tracheoesophageal fistula
Anal fistula
Neuromuscular junction disorders: Pathology review
Muscular dystrophy
Muscular dystrophies and mitochondrial myopathies: Pathology review
Carpal tunnel syndrome
Erb-Duchenne palsy
Klumpke paralysis
Compartment syndrome
Sciatica
Achondroplasia
Osteomyelitis
Paget disease of bone
Sjogren syndrome
Systemic lupus erythematosus
Antiphospholipid syndrome
Raynaud phenomenon
Polymyositis
Dermatomyositis
Polymyalgia rheumatica
Lambert-Eaton myasthenic syndrome
Myasthenia gravis
Fibromyalgia
Septic arthritis
Rheumatoid arthritis
Gout
Osteoarthritis
Psoriatic arthritis
Ankylosing spondylitis
Reactive arthritis
Pheochromocytoma
Dementia and delirium: Clinical
Medication overdoses and toxicities: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Drug misuse, intoxication and withdrawal: Stimulants: Pathology review
Drug misuse, intoxication and withdrawal: Other depressants: Pathology review
Drug misuse, intoxication and withdrawal: Alcohol: Pathology review
Dissociative disorders: Clinical
Anxiety disorders: Clinical
Somatic symptom disorders: Clinical
Toxidromes: Clinical
Perinatal infections: Clinical
Congenital TORCH infections: Pathology review
Kawasaki disease: Clinical
Developmental milestones: Clinical
Sickle cell disease: Clinical
Pediatric bone and joint infections: Clinical
Skin and soft tissue infections: Clinical
Viral exanthems of childhood: Pathology review
Elimination disorders: Clinical
Neurodevelopmental disorders: Clinical
Cystic fibrosis: Clinical
Pediatric orthopedic conditions: Clinical
Migraine medications
Osteoporosis medications
Benign breast conditions: Pathology review
Multiple sclerosis
Meningitis
Intracerebral hemorrhage
Subarachnoid hemorrhage
Parkinson disease
Guillain-Barre syndrome
Seronegative arthritis: Clinical
Scleroderma: Pathology review
Scleroderma
Yellow fever virus
Zika virus
Ovarian germ cell tumors
Ovarian cysts, cancer, and other adnexal masses: Clinical
Ovarian cyst
Ascending and descending spinal tracts
Muscle weakness: Clinical

Transcript

Watch video only

At the clinic, 32 year old mary comes with her 6 year old son thomas, after noticing he’s often clumsy, weak, and has trouble climbing the stairs of their house. Mary is worried because she had a brother who presented the same symptoms as a child, and developed progressive weakness, until he passed away at 23 years old due to respiratory problems. Upon physical examination, the physician notices that thomas has scoliosis and thick calves. Later that day, 29 year old sarah comes to the clinic with her 10 year old son mike because of progressive muscle weakness and fatigue, as well as vomiting and loss of appetite. In addition, she mentions that he has experienced seizures.

Based on the clinical findings, the physician concludes that both children have some form of inherited muscular disorder, and orders genetic testing to confirm the diagnosis. Now, let’s go over the two main groups: muscular dystrophies and mitochondrial myopathies.

Muscular dystrophies are a group of genetic disorders characterized by muscle degeneration and weakness. Within that group, dystrophinopathies are the most common, and this includes duchenne muscular dystrophy, or dmd for short, and becker muscular dystrophy, or bmd.

Both duchenne and becker result from mutations in the dystrophin gene, which is found on the x chromosome. For your exams, remember that these are x-linked recessive disorders, which means that all carrier males develop the disease, because they only have one x chromosome and thus one dystrophin gene available. On the other hand, females have two x chromosomes, so even if they have a defective dystrophin gene on one x chromosome, they still have another functional one. However, only one x chromosome gets expressed and the other is inactivated through a process called x-inactivation or lyonization. This inactivation is random which means that every cell could have a chance of having the mutated x chromosome be the active copy. If this is the case for more than half of the muscle cells, they will be a manifesting carrier who will develop symptoms. People with more cells with the active mutated x chromosome will have more severe symptoms and quicker disease progression. If less than half of their cells have the active mutated x chromosome, they’ll be an asymptomatic carrier and won’t develop symptoms.

Now, long story short, dystrophin is a protein found on the plasma membrane of muscle fibers to provide mechanical reinforcement and stabilization. As a result, having defective dystrophin proteins leads to degeneration and instability of muscle fibers, in turn causing muscle weakness. What determines which disease you get is the type of mutation in the dystrophin gene. Duchenne muscular dystrophy results when the mutation results in no protein being produced at all, for example a nonsense or a frameshift mutation. On the other hand, becker muscular dystrophy results from mutations like missense mutations that allow a misshapen and partially functional protein to be produced. So, what's especially high yield is that duchenne ends up being the more severe of the two, with symptoms usually presenting by the age of 5, while becker is basically a milder form of duchenne that presents later on, usually between the ages 10 to 20.

In both disorders, initially, there’s muscle regeneration to compensate for the muscle degeneration and weakness. Over time, the muscle tissue can’t keep up, so it atrophies and gets infiltrated by fat and fibrotic tissue. This process can occur in any muscle, but it is most noticeable in the muscle of the legs. In a test question, this will classically manifest as calf pseudohypertrophy, where the calves are visibly enlarged, but that's because of fat and fibrotic tissue rather than actual muscle tissue. As muscle weakness progresses, individuals have a progressive difficulty walking. A very high yield sign is the waddling gait. This is due to the pelvic girdle muscles becoming weak so the individual will have problems with balance. So to compensate, they will walk by taking short steps while swinging their trunk side to side with each step as a counter balance. Muscles around the hips and upper legs can also weaken, making it hard for these individuals to stand up. Now, an important term to remember is gowers’ sign, which is when an individual that’s lying on their stomach needs to use their arms to slowly “walk” back up in order to stand. Individuals can also develop skeletal deformities like scoliosis or hyperlordosis. As muscle weakness progresses, most individuals with duchenne may end up needing a wheelchair by the age of 13, and can become paralyzed from the neck down by the time they’re 21 years old. On the other hand, for individuals with becker, this progression is usually delayed by about 10 years.

Eventually, individuals end up developing serious complications, including respiratory failure because of a weak diaphragm, and dilated cardiomyopathy and arrhythmias, since the dystrophin protein is also expressed in heart muscle. Unfortunately, these complications often lead to a shortened lifespan. Most individuals with duchenne die in their 20s, and those with becker in their 40s.

For diagnosis, people with suspected duchenne or becker muscular dystrophy on physical examination should get appropriate testing. The first step is getting blood tests for creatine kinase or ck. If ck levels are high, diagnosis can be confirmed through genetic testing that looks for mutations in dystrophin either with a western blot test or dna tests. Rarely, if genetic testing is inconclusive, a muscle biopsy with staining for dystrophin will be required. Remember that we expect to see an absence of dystrophin in duchenne, and abnormal dystrophin in becker.

Unfortunately, there is no cure for muscular dystrophies. Glucocorticoids can sometimes slow degeneration, but they should be used in moderation, since they are typically also accompanied by side effects like excessive weight gain. Other treatments like physical therapy and conditioning can improve quality of life, but they don’t reverse the underlying process.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Distal muscular dystrophies" Handbook of Clinical Neurology (2011)
  4. "Muscular Dystrophies" Elsevier Science Limited (2011)
  5. "Facioscapulohumeral Muscular Dystrophy" CONTINUUM: Lifelong Learning in Neurology (2016)
  6. "Cognitive Neuroscience: The Biology of the Mind (Fourth Edition)" W. W. Norton (2013)
  7. "Loose-leaf Version for Genetics: A Conceptual Approach" Macmillan Higher Education (2019)
  8. "Inheritance of most X-linked traits is not dominant or recessive, just X-linked" American Journal of Medical Genetics (2004)